SCC breast implant capsule evidence concerns extremely rare reports of squamous cell carcinoma (SCC) and lymphomas other than BIA-ALCL in the scar capsule that forms around a breast implant. These reports deserve careful attention, but they do not establish a known incidence, a proven cause or a simple individual risk calculation. The evidence is mainly case reports, case series, literature reviews and passive medical-device reports—sources that can identify a safety signal but cannot measure how often it occurs among all people with implants.
This review of SCC breast implant capsule evidence explains what regulators have reported, distinguishes SCC and rare B-cell lymphomas from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and describes why new swelling, pain, a mass or a late fluid collection needs assessment. It does not imply that routine preventive implant removal is recommended for people without symptoms, and it does not diagnose a cancer from symptoms or an image.
What the FDA safety communication says
In September 2022, the U.S. Food and Drug Administration (FDA) informed the public that it had received reports of cancers, including SCC and various lymphomas, in the capsule around breast implants. In its March 2023 update, the FDA stated that it was aware of 19 published SCC cases in the implant capsule and 24 medical device reports related to SCC as of January 15, 2023. The agency continued to regard the occurrences as rare while stating that the cause, incidence and risk factors were unknown.
Case reports involved both saline and silicone gel-filled implants when implant information was available, and reports included smooth and textured surfaces. Many people were diagnosed years after their first implant placement. These observations must not be used to say that a particular filler, surface or implant age causes SCC. Information is incomplete in many reports, some patients have had more than one device over time and there is no denominator showing the number of people with comparable implants who never developed the disease.
The FDA encourages reporting of SCC, various lymphomas and other cancers in an implant capsule to the FDA and the PROFILE Registry. This surveillance matters because rare-event knowledge improves when pathology, device history, treatment and outcome are recorded consistently. It also explains why the evidence may change: an emerging signal is monitored, not treated as a finished estimate.
SCC, BIA-ALCL and other lymphomas are not the same entity
SCC is a carcinoma: it arises from epithelial-type cells. BIA-ALCL is a distinct CD30-positive, ALK-negative T-cell lymphoma occurring in the fluid or capsule around an implant and has its own history of surface association, diagnostic pathway and treatment guidance. The FDA explicitly states that the “various lymphomas” in its SCC safety communication are not the same as BIA-ALCL. Conflating these diseases can distort risk communication and delay the correct pathological work-up.
Rare B-cell lymphomas have also been reported in implant capsules. Some are Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphomas with features that overlap with fibrin-associated large B-cell lymphoma, while other reports describe marginal-zone lymphoma. These are far too uncommon for confident population risk estimates. They may resemble BIA-ALCL clinically or morphologically, so a pathology assessment needs lineage-specific B-cell and T-cell markers as well as EBV testing when indicated. A label such as “implant-associated lymphoma” is not enough to choose treatment.
A 2021 report of two EBV-positive large B-cell lymphomas confined to the implant capsule and a 2021 analysis of eight cases both highlighted the possibility of a chronic inflammatory microenvironment and EBV involvement. These are biologically interesting hypotheses, not proof that implants cause every reported B-cell lymphoma. A 2024 molecular case report likewise stressed how few cases exist and the importance of full capsule examination and registry reporting. Case literature is especially susceptible to publication bias: unusual, severe or diagnostically complex cases are more likely to appear in journals.
How these rare conditions may present
Published reports describe symptoms such as new breast swelling, pain, enlargement, a late fluid collection, a mass, capsular contracture or skin change. None is specific to SCC or lymphoma. More common possibilities include benign fluid, infection, bleeding, implant rupture, capsule tightening or ordinary breast disease. The appropriate message is neither alarm nor dismissal: a new or persistent breast change after implantation should be assessed by the clinical team, particularly when it is delayed or progressive.
Assessment may include clinical examination, ultrasound of the breast and regional nodes, aspiration of a clinically significant late fluid collection when appropriate, imaging selected for the finding, and pathology review of fluid, a mass or capsule tissue. The exact work-up depends on the presentation and specialist judgment. Pathology is central because imaging cannot determine cell type. If a tumour is identified, staging and management should involve an experienced multidisciplinary team; the plan differs sharply between a localized capsule process and invasive or systemic disease.
Do not interpret a routine scan, an online photo, implant rippling or ordinary early postoperative swelling as evidence of one of these rare diseases. Conversely, do not wait for a scheduled surveillance visit if there is rapid new swelling, a growing mass, persistent unexplained pain, a significant shape change, ulceration or another concerning symptom. The BIA-ALCL evidence review addresses a different, specific implant-associated lymphoma and its established diagnostic context.
What is known about risk factors—and what is not
For SCC in the capsule, the FDA’s 2023 review did not identify a known cause, incidence or risk factors. Reports included different implant fillers and surfaces. This is meaningfully different from BIA-ALCL, for which regulator communications and epidemiology have identified a stronger association with textured devices. A safety signal in a capsule is not evidence that all capsule cancers share the same mechanism or risk profile.
For non-ALCL lymphomas, the literature has insufficient numbers and heterogeneity to establish whether implants, chronic inflammation, EBV, host immune status, capsule biology or chance co-occurrence is responsible in a particular case. EBV-positive B-cell lymphomas may be classified differently depending on their growth pattern and pathological features. A small number of favourable outcomes after capsule excision should not become a universal treatment claim: invasive disease, systemic disease and a different histological diagnosis may require different management.
The duration of implantation reported in cases also cannot be interpreted as a threshold. Many diagnoses occurred years after first implantation, but that may reflect exposure time, reporting patterns, patient age or an underlying condition rather than a point at which cancer becomes expected. Breast implants are not lifetime devices, but implant longevity counselling should remain separate from an unsupported claim that a person must replace an intact implant to prevent SCC or an unspecified lymphoma.
Why surveillance and reporting are central
Rare adverse-event evidence often starts with case reports and voluntary reports. These systems are valuable for detecting patterns that routine trials are too small or too short to see. They cannot establish incidence because reports may be duplicated, incomplete, stimulated by media attention or missing a verified denominator. Published cases can be more detailed but are not a representative sample. The FDA’s ongoing review and PROFILE reporting are therefore part of the evidence, not evidence of a fixed rate.
Useful reporting includes the original and most recent implant information, surface and filler where known, timing, symptoms, imaging, full pathology, treatment and follow-up. This is particularly important when a patient has had previous implant exchanges, because current device surface may not represent historical exposure. It also helps future researchers distinguish SCC, BIA-ALCL, EBV-positive B-cell disease, ordinary breast cancers and non-neoplastic capsule findings.
Implications for people with implants
The FDA does not recommend prophylactic removal of breast implants for people without symptoms solely because of SCC or various lymphoma reports. A person with implants should continue routine healthcare, breast-cancer screening appropriate to age and risk, and device follow-up discussions. For silicone implants, see the ultrasound and MRI rupture-screening evidence; implant-integrity surveillance is not a cancer screening programme.
It is useful to keep a device card and operative history. If a new problem occurs, this information helps clinicians identify the implant and assess prior procedures. A consultation should make room for questions about the specific symptom, the likely common causes, the test being proposed, what tissue may be sent to pathology and how results will be communicated. The practical breast-implant safety guide gives patient-facing background but cannot replace urgent clinical advice.
Evidence limitations
The central limitation is rarity. Nineteen published SCC cases in the FDA’s 2023 review and fewer than 30 published various lymphomas in related labeling do not permit a reliable rate, a comparison by surface or a causal conclusion. Reports may lack complete implant history, pathology review, outcome data and a denominator. The number of known cases is not the risk for an individual and should not be converted to a percentage without a validated population study.
Terminology and classification continue to develop, particularly for EBV-positive large B-cell processes. Treatment reports are subject to selection bias and short follow-up. The best current practice is proportionate vigilance: recognise a concerning change, investigate it properly, distinguish the pathology, report verified cases and update advice when regulatory or pathological evidence advances.
Conclusion
Current SCC breast implant capsule evidence confirms a rare safety signal, not a settled causal or incidence estimate. SCC and lymphomas other than BIA-ALCL have been reported in the capsule around implants, across incomplete histories of different implant types. They are distinct diseases requiring distinct pathology and management.
People with implants should not be alarmed into unneeded surgery, but new swelling, a mass, persistent pain, late fluid or another significant change deserves prompt clinical assessment. Surveillance systems, complete pathology and responsible reporting are the route to better answers. Until stronger evidence exists, the most accurate communication is transparent about both the seriousness of a possible malignancy and the profound uncertainty created by its rarity.
Frequently asked questions
Is SCC around a breast implant the same as BIA-ALCL?
No. SCC is a carcinoma, while BIA-ALCL is a specific T-cell lymphoma. The FDA states that various lymphomas reported in capsule safety communications are not the same as BIA-ALCL.
How common is SCC in an implant capsule?
The FDA considers reported occurrences rare, but incidence and risk factors remain unknown. Case reports and device reports cannot provide a reliable individual percentage.
Do smooth or silicone implants eliminate the risk?
No conclusion of elimination is supported. FDA-reported SCC cases included different fillers and, where history was known, smooth and textured implants. Evidence is insufficient to assign causation by device type.
What symptoms need assessment?
New swelling, a growing mass, persistent pain, late fluid collection, significant shape change, skin change or another concerning new breast symptom should be assessed promptly. These symptoms are not specific for cancer.
Should people without symptoms remove implants to prevent SCC?
The FDA does not recommend prophylactic removal solely because of SCC or various lymphoma reports in people without symptoms. Individual implant decisions should be discussed with a qualified surgeon.
Can imaging alone diagnose these rare cancers?
No. Imaging can identify a fluid collection or mass, but pathology determines the cell type. Specialist assessment may include fluid or tissue sampling and multidisciplinary review.
Sources and references
- FDA Safety Communication: SCC in the capsule around breast implants, updated March 2023.
- FDA CDRH update on SCC in scar tissue around breast implants, 2023.
- Breast implant-associated squamous cell carcinoma: systematic literature review, 2023.
- EBV-positive large B-cell lymphoma associated with breast implants: analysis of eight patients, 2021.
- Breast implant-associated EBV-positive diffuse large B-cell lymphoma: two cases and review, 2021.
- Breast implant-associated EBV-positive diffuse large B-cell lymphoma: an underrecognized entity?, 2023.
- Fibrin-associated large B-cell lymphoma identified in a breast implant capsule, 2024.
- FDA Risks and Complications of Breast Implants. Current regulator information and reporting context.
Author and medical-review metadata
Author: BreastAugmentationInTurkey.org Editorial Team
Medical reviewer: Independent qualified plastic and reconstructive surgeon — medical reviewer to be confirmed before publication
Published: 11 September 2026
Evidence updated: 11 September 2026
Scope: Educational safety-signal review for people with breast implants; cosmetic augmentation, reconstruction and revision reports are not combined as equivalent evidence.
Editorial limitation: This article cannot diagnose a malignancy or recommend individual treatment. It should be updated if regulator or pathology guidance materially changes.